DO YOU OR SOMEONE YOU KNOW HAVE BENIGN PROSTATIC HYPERPLASIA (BPH)?

20192730 #26223800.0 IRB Approved at the Protocol Level Dec 26, 2019

Patients may be eligible to participate in the study if:

- ✓ they are a man age 50-80
- \checkmark they have been diagnosed with symptomatic BPH
- ✓ they have a history of poor response or refusal of BPH medication

What is the purpose of the research study?

The study is designed to assess the safety and efficacy of Optilume BPH[™] in the treatment of BPH.

What is Optilume BPH[™] and how is it used?

Treatment with the Optilume BPH Catheter System[™] is a simple, outpatient procedure that combines balloon dilation to open the prostate and local drug delivery designed to reduce the need for retreatment. The investigational treatment takes about fifteen minutes and is done on an outpatient basis.

Subjects may receive a travel stipend.

Early results from the EVEREST-1 study indicate that the Optilume BPH™ treatment is effective in alleviating lower urinary tract symptoms (LUTS) and improving patient quality of life.

99% improvement in urinary flow at 6 months (Qmax) 64% improvement in symptoms at 6 months (IPSS)

Data on file, Urotronic Inc.

Key Benefits of Optilume BPH[™]:

- Rapid symptom relief and return to normal activities
- Preserves sexual function
- No burning, cutting or permanent implant
- Simple outpatient therapy

If you're interested in this study, contact James Knutson - 847-852-4306